IMMUNIZATION OF COTTONTOP TAMARINS AND RABBITS WITH A CANDIDATE VACCINE AGAINST THE EPSTEIN-BARR-VIRUS BASED ON THE MAJOR VIRAL ENVELOPE GLYCOPROTEIN GP340 AND ALUM
IMMUNIZATION OF COTTONTOP TAMARINS AND RABBITS WITH A CANDIDATE VACCINE AGAINST THE EPSTEIN-BARR-VIRUS BASED ON THE MAJOR VIRAL ENVELOPE GLYCOPROTEIN GP340 AND ALUM
复制标题
DOI：
10.1016/0264-410x(94)90240-2
复制
发表时间：
1994-10-01
期刊：
影响因子：
5.5
通讯作者：
MORGAN, AJ
中科院分区：
文献类型：
--
作者：
FINERTY, S;MACKETT, M;MORGAN, AJ
EB病毒（EBV）与人类的一系列危及生命的疾病有关。因此，开发有效的疫苗是一个重要目标。开发用于人类施用的亚单位疫苗的一个问题是选择令人满意的佐剂，因为目前唯一被许可用于人类使用的佐剂是明矾，尽管这被认为不是非常有效。本研究表明，由EBV包膜糖蛋白gp 340与明矾作为佐剂组成的亚单位疫苗确实在五分之三的棉顶绢毛猴中引起针对EBV诱导的淋巴瘤的保护性免疫。此外，用gp 340/明矾免疫的兔产生与用gp 340/SAF-1免疫的兔相同范围的抗体应答，所述实验佐剂声称比明矾更有效。因此，这些结果表明，明矾应该作为基于gp 340的亚单位疫苗的人体试验的一部分作为佐剂进行评估。
The Epstein-Barr virus (EBV) is associated with a range of life-threatening diseases in humans. Development of an effective vaccine has therefore been an important objective. One problem in the development of a subunit vaccine for human administration is the selection of a satisfactory adjuvant since the only one currently licensed for human use is alum, although this is not considered to be very effective. The present study demonstrated that a subunit vaccine composed of the EBV envelope glycoprotein gp340 with alum as the adjuvant did elicit protective immunity against EBV-induced lymphoma in three out of five cottontop tamarins. Furthermore, rabbits immunized with gp340/alum developed the same range of antibody responses as rabbits immunized with gp340/SAF-1, an experimental adjuvant claimed to be more effective than alum. Therefore, these results indicate that alum should be evaluated as an adjuvant as part of a human trial of a gp340-based subunit vaccine.